Early predictors of prolonged overall survival (OS) in patients (pts) on first-line chemotherapy (CT) for metastatic colorectal cancer (mCRC): An ARCAD study with individual patient data (IPD) on 10,962 pts.

Sommeijer, Dirkje W.; Saad, Saad; Coart, Els; Buyse, Marc; Burzykowski, Tomasz; Meyers, Jeffrey P.; Maughan, T; Adams, Richard; Seymour, Michel; Saltz, Leonard; Goldberg, Richard M.; Jy, Douillard; Schmoll, H.-J.; Cja., Punt; Tournigand, C.; Chibaudel, Benoist; Gramont, Aimery de; Sargent, Daniel J.; Zalcberg,; Arcad., Grp

doi:10.1200/jco.2014.32.15_suppl.3538

Cited by 3 publications

(1 citation statement)

References 0 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…In a similar study, Sommeijer et al compared markers of early response at 6, 8/9, or 12 weeks with the standard response endpoints of best overall response and confirmed response, in patients treated only with chemotherapy, as predictors of PFS and OS (33). All the patients in this analysis were treated with 5FU-LV or capecitabine alone or with the addition of oxaliplatin and/or irinotecan.…”

Section: Response-based Endpointsmentioning

confidence: 99%

Clinical Trial Endpoints in Metastatic Cancer: Using Individual Participant Data to Inform Future Trials Methodology

Goldberg

Adams

Buyse

et al. 2021

JNCI: Journal of the National Cancer Institute

Self Cite

View full text Add to dashboard Cite

Meta-analysis based upon individual participant data (IPD) is a powerful methodology for synthesizing evidence by combining information drawn from multiple trials. Hitherto, its principal application has been in questions of clinical management, but an increasingly important use is in clarifying trials methodology, for instance in the selection of endpoints, as discussed in this review. In oncology, the Aide et Recherche en Cancérologie Digestive (ARCAD) Metastatic Colorectal Cancer Database is a leader in the use of IPD-based meta-analysis in methodological research. The ARCAD database contains IPD from over 38,000 patients enrolled in 46 studies and continues to collect Phase III trial data. Here, we review the principal findings of the ARCAD project in respect of endpoint selection and examine their implications for cancer trials. Analysis of the database has confirmed that progression-free survival (PFS) is no longer a valid surrogate endpoint predictive of overall survival in the first-line treatment of colorectal cancer. Nonetheless, PFS remains an endpoint of choice for most first-line trials in metastatic colorectal cancer and other solid tumors. Only substantial PFS effects are likely to translate into clinically meaningful benefits, and accordingly we advocate an oncology research model designed to identify highly effective treatments in carefully defined patient groups. We also review the use of the ARCAD database in assessing clinical response including novel response metrics, and prognostic markers. These studies demonstrate the value of IPD as a tool for methodological studies and provide a reference point for the expansion of this approach within clinical cancer research.

show abstract

Section: Response-based Endpointsmentioning

confidence: 99%